ClinicalTrials.gg
CompletedNCT00062582Updated Nov 23, 2016

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

A Phase 3 interventional study of Roflumilast in Chronic Obstructive Pulmonary Disease and COPD, sponsored by AstraZeneca. Completed at 37 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
9th of 32
1,000 · median 154
Started
2003
with 2 others
Phase 3
16 of 32
none open now
Registered
1st of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 9th largest by enrollment, is one of 3 that started in 2003, is one of 16 in phase 3, and was the 1st registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • COPD

Keywords

  • Roflumilast
  • Chronic Obstructive Pulmonary Disease
  • COPD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Clinical diagnosis of (Chronic Obstructive Pulmonary Disease)
  • Currently stable COPD with no change in COPD treatment in the prior 4 weeks

Main Exclusion Criteria:

  • Clinical diagnosis of asthma
  • Poorly controlled COPD
  • Regular need for daily oxygen therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. pulmonary function.

Secondary outcomes

  1. exacerbation rate

  2. quality of life

  3. symptoms

  4. use of rescue medication

  5. safety and tolerability.

07

Study locations

37 sites
  • ALTANA Pharma
    Cities in Alabama, Alabama, United States
  • ALTANA Pharma
    Cities in Arizona, Arizona, United States
  • ALTANA Pharma
    Cities in California, California, United States
  • ATLANA Pharma
    Cities in Colorado, Colorado, United States
  • ALTANA Pharma
    Cities in Conneticut, Connecticut, United States
  • ALTANA Pharma
    Cities in Delaware, Delaware, United States
  • ALTANA Pharma
    Cities in Florida, Florida, United States
  • ALTANA Pharma
    Cities in Georgia, Georgia, United States
  • ALTANA Pharma
    Cities in Idaho, Idaho, United States
  • ALTANA Pharma
    Cities in Indiana, Indiana, United States
  • ALTANA Pharma
    Cities in Iowa, Iowa, United States
  • ALTANA Pharma
    Cities in Kansas, Kansas, United States
  • ALTANA Pharma
    Cities in Kentucky, Kentucky, United States
  • ALTANA Pharma
    Cities in Louisiana, Louisiana, United States
  • ALTANA Pharma
    Cities in Maryland, Maryland, United States
  • ALTANA Pharma
    Cities in Michigan, Michigan, United States
  • ALTANA Pharma
    Cities in Missouri, Missouri, United States
  • ALTANA Pharma
    Cities in Nebraska, Nebraska, United States
  • ALTANA Pharma
    Cities in Nevada, Nevada, United States
  • ALTANA Pharma
    Cities in New Jersey, New Jersey, United States
  • ALTANA Pharma
    Cities in New York, New York, United States
  • ALTANA Pharma
    Cities in North Carolina, North Carolina, United States
  • ALTANA Pharma
    Cities in Ohio, Ohio, United States
  • ALTANA Pharma
    Cities in Oregon, Oregon, United States
  • ALTANA Pharma
    Cities in Pennsylvania, Pennsylvania, United States
  • ALTANA Pharma
    Cities in Rhode Island, Rhode Island, United States
  • ALTANA Pharma
    Cities in South Carolina, South Carolina, United States
  • ALTANA Pharma
    Cities in Texas, Texas, United States
  • ALTANA Pharma
    Cities in Utah, Utah, United States
  • ALTANA Pharma
    Cities in Virginia, Virginia, United States
  • ALTANA Pharma
    Cities in Washington, Washington, United States
  • ALTANA Pharma
    Cities in West Virginia, West Virginia, United States
  • ALTANA Pharma
    Cities in Argentina, Argentina
  • ALTANA Pharma
    Cities in Canada, Canada
  • ALTANA Pharma
    Cities in Colombia, Colombia
  • ALTANA Pharma
    Cities in Mexico, Mexico
  • ALTANA Pharma
    Cities in Peru, Peru
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00062582
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 10, 2003
Start date
Jun 2003
Last update
Nov 23, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion